

OncoSTRAT&GO

SOLID PART

GENES									
ABL1	ACVRL1	AKT1	ALK	APC	APEX1	AR	ARAF	ASXL1	ATM
ATP11B	AURKA	BAP1	BCL2L1	BCL9	BIRC2	BIRC3	BRAF	BRCA1	BRCA2
BTK	CBL	CCND1	CCNE1	CD274	CD44	CDH1	CDK4	CDK6	CDKN2A
CHEK2	CSF1R	CSNK2A1	CTNNA1	CYP2C19	CYP2D6	DCUN1D1	DDR2	DNMT3A	DPYD
EGFR	EPHA3	EPHA5	EPHB1	ERBB2	ERBB3	ERBB4	ERRF1	ESR1	EZH2
FANCA	FANCC	FANCD2	FANCE	FANCF	FANCG	FANCL	FAS	FBXW7	FGFR1
FGFR2	FGFR3	FGFR4	FLNC	FLT1	FLT3	FLT4	FOXL2	GAS6	GATA1
GATA2	GATA3	GATA6	GNA11	GNA13	GNAQ	GNAS	H3F3A	HGF	HNF1A
HRAS	IDH1	IDH2	IFITM1	IFITM3	IGF1R	IKBKE	IL6	INHBA	IRF2
JAK1	JAK2	JAK3	KDR	KEAP1	KEL	KIT	KNSTRN	KRAS	LYN
MAGOH	MAP2K1	MAP2K2	MAPK1	MAX	MCL1	MDM2	MDM4	MED12	MET
MLH1	MPL	MRE11A	MSH2	MTOR	MYC	MYCL	MYCN	MYD88	MYO18A
NF1	NF2	NFE2L2	NKX2-1	NKX2-8	NOTCH1	NPM1	NRAS	NTRK1	NTRK3
PALB2	PAX5	PDCD1LG2	PDGFRA	PDGFRB	PIK3CA	PIK3CB	PIK3CG	PIK3R1	PIK3R2
PNP	POLD1	POLE	PPARG	PRKCI	PRKDC	PTCH1	PTEN	PTPN11	PTPRD
RAC1	RAD51	RAD51C	RAF1	RARA	RB1	RET	RHEB	RHOA	RNF43
ROS1	RPS6KB1	RPTOR	RUNX1	RUNX1T1	SETD2	SF3B1	SMAD4	SMARCA4	SMARCB1
SMO	SOX2	SPOP	SRC	STAT3	STK11	TERT	TET2	TGBR2	TIAF1
TOP1	TOP2A	TP53	TPMT	TSC1	TSC2	TSHR	U2AF1	UTG1A1	VHL
WT1	XPO1	ZNF217							

LIQUID PART

GENES									
AKT1	ALK	AR	BRAF	BTK	cKIT	cMET	CTNNA1	DDR2	EGFR
ERBB2	ESR1	EZH2	FBXW7	FGFR1	FGFR2	FGFR3	FOXL2	GNA11	GNAQ
GNAS	HRAS	IDH1	IDH2	JAK2	JAK3	KRAS	MAP2K1	MAP2K2	MPL
MTOR	NMP1	NRAS	PDGFRA	PIK3CA	PTEN	RAF1	RET	ROS1	TP53

GENE : Additional genes included in this new version of the panel are highlighted in green.
 One gene was added to the solid part of the new OncoSTRAT&GO panel, and some regions in other genes have been enriched.

We improved OncoSTRAT&GO® by adding:

1. Genes mainly dedicated to immuno and targeted therapies (especially in the liquid biopsy)
2. MSI (Microsatellite Instability) testing for Immunotherapy and resistance to 5-FU based chemotherapies
3. TMB (Tumor Mutational Burden) analysis for Immunotherapy
4. Highly polymorphic SNPs to detect hemizygoty or LOH (Loss of Heterozygoty) for targeted therapies or prognosis

